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ABSTRACT
Background: Individuals with low serum vitamin B-12 and high serum folate have higher plasma concentrations of
methylmalonic acid (MMA). Whether folic acid (FA) causes an increase in MMA is not known.
Objectives: We aimed to determine the impact of FA supplementation on plasma MMA concentration in people with
low or marginal serum vitamin B-12.
Methods: We conducted a multicenter double-blind placebo-controlled randomized trial of oral FA (5 mg/d for 12 wk)
in middle-aged patients treated with antidepressant medication participating in the FoLATED (Folate Augmentation of
Treatment—Evaluation for Depression) trial. Participants defined as having “low” serum vitamin B-12 (vitamin B-12 ≥150
and <220 ng/L) or “marginal” serum vitamin B-12 (vitamin B-12 ≥ 220 and <280 ng/L) were included. The primary
outcome of this substudy was MMA at week 12. A mixed-effects linear regression was fitted and reported using the
adjusted mean difference (aMD).
Results: A total of 177 participants were included (85 randomly assigned to placebo and 92 to FA); the mean ± SD age
was 46.2 ± 11.8 y, and 112 (63.3%) were female. The MMA analysis included 135 participants and the aMD was −0.01
(95% CI: −0.06, 0.04; P = 0.71). Serum folate was measured on 166 participants and increased in the supplementation
group; the aMD was 21.6 μg/L (95% CI: 8.13, 25.02 μg/L; P < 0.001). A total of 117 participants were assessed for RBC
folate, which also increased in the supplementation group; the aMD was 461 μg/L (95% CI: 387, 535 μg/L; P < 0.001).
Conclusions: Supplementation of FA leads to an increase of serum and RBC folate, but does not change plasma
MMA concentration in individuals with serum vitamin B-12 between 150 and 280 ng/L. We cannot exclude effects in
older people or those with serum vitamin B-12 <150 ng/L. Previously reported associations may arise from effects of
impaired vitamin B-12 status on folate metabolism. This trial was registered at www.isrctn.com as ISRCTN37558856.
J Nutr 2021;00:1–8.
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Introduction
The interaction between vitamin B-12 and folate has important
public health implications. For example, folic acid (FA) supple-
mentation corrects the anemia of vitamin B-12 deficiency but
not vitamin B-12–related neurological changes (1). Permanent
nerve damage might occur if vitamin B-12 deficiency remains
untreated, although the evidence for such “masking” is scarce,
even after folate fortification of food (2). The rationale
for many countries to introduce such fortification was to
reduce the incidence of neural tube defects (3), and this has
proved remarkably successful (4). However, the combination of
mandatory fortification and self-supplementation has exposed
a significant proportion of these populations to concentrations
of FA above the upper intake level (5).
This has led to various concerns regarding the potential tox-
icity of such exposure. These include possible associations with
an increased incidence of colorectal and breast cancers, autism,
and cognitive function (5), although significant controversy
exists (6). For example, in areas with mandatory fortification,
high serum folate combined with low serum vitamin B-12
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is associated with cognitive impairment in the elderly (7–
10). However, no such association is observed in nonfortified
countries (11, 12).
A cross-sectional study of >10,000 participants in the US
NHANES observed a relation between serum folate and a
metabolic marker of an enzymatic function of vitamin B-
12 (13). The vitamin B-12–dependent enzyme methylmalonyl
CoA mutase converts methylmalonyl-CoA to succinyl-CoA.
Plasma methylmalonic acid (MMA) concentration increases
with suboptimal serum vitamin B-12 and, in the absence
of renal impairment, is a useful functional marker of its
status. However, in individuals with low serum vitamin B-
12 (<148 pmol/L ∼ 200 ng/L) in the NHANES study, mean
MMA concentration increased significantly with increasing
serum folate (P = 0.008) (13).
There is little prior evidence that FA affects MMA accumu-
lation and biologically one might not expect any interaction
between these 2 molecules. However, several other cross-
sectional reports have also suggested that this might occur in
the context of high FA intake from mandatory fortification of
foods plus high supplement usage (14). The question is relevant
because it might provide evidence that high FA intake interferes
with vitamin B-12 metabolism.
One hypothetical explanation is an adverse oxidative effect
of unmetabolized FA (UMFA) on vitamin B-12 homeostasis
(13). Alternatively, people with existing low vitamin B-12
might fail to synthesize polyglutamated intracellular folate—
an essential prerequisite for its cellular retention—hence
accounting for the observed cross-sectional association between
MMA and serum folate (15).
There is a high prevalence of metabolic vitamin B-12 defi-
ciency in the elderly (16). This is associated with lower cognitive
function scores (17). If FA increases MMA concentration, this
is vitally important for public health decisions concerning food
fortification (6, 18).
It is impossible to distinguish cause from effect in cross-
sectional studies (19, 20). We designed the FolATED (Folate
Augmentation of Treatment—Evaluation for Depression) trial
to investigate FA augmentation of antidepressive treatment by
randomly assigning patients to either 5 mg of FA or placebo
daily (21).
The objective of this substudy was to assess the effect of FA
supplementation on MMA concentration in patients with low
or marginal vitamin B-12 concentrations.
Methods
Patients
FolATED was a double-blind, placebo-controlled randomized trial
conducted across 3 UK centers (22). Between July 2007 and November
The FolATED (Folate Augmentation of Treatment—Evaluation for Depression)
trial (21) was supported by UK National Institute of Health Research Health
Technology Assessment programme project number 04/35/08 (to ITR). The
funder played no role in designing and implementing the trial or analyzing and
interpreting data; the full trial was published in Health Technology Assessment
2014;18(48) (22).
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Abbreviations used: aMD, adjusted mean difference; FA, folic acid; Fo-
lATED, Folate Augmentation of Treatment—Evaluation for Depression; MMA,
methylmalonic acid; MREC, Multicenter Research Ethics Committee; UMFA,
unmetabolized folic acid; 5mTHF, 5-methyl-tetrahydrofolate.
2010 we recruited a sample of people with moderate to severe
depression from primary or secondary care in 3 centers across Wales,
United Kingdom. Of the 475 patients randomized to daily placebo or
5 mg FA daily for 12 wk, we included 440 in the FolATED analysis
by treatment allocated. The substudy inclusion criteria were patients
having low (150–219.9 ng/L) or marginal (220–280 ng/L) serum
vitamin B-12 at recruitment. Blood samples were taken at baseline and
at 12 wk.
Settings
Three centers throughout Wales were involved with recruitment: North
East Wales, North West Wales, and Swansea.
Randomization
The sequence was generated using a varying permuted block design
stratified by site.
Laboratory methods
Serum and RBC folate and serum vitamin B-12 were analyzed at local
National Health Service laboratories on the day of collection. “Access”
folate and vitamin B-12 chemiluminescence immunoassays (Beckman
Coulter) were used in North East and North West Wales, whereas “Elec-
sys” folate and vitamin B-12 electrochemiluminescence immunoassays
(Roche) were used in Swansea. We undertook biochemical analyses in
the Department of Medical Biochemistry at the University Hospital of
Wales in Cardiff. The samples for homocysteine and MMA were stored
frozen at −70◦C until completion of the study. We measured plasma
homocysteine using a commercially available assay for the Abbott
Diagnostics ARCHITECT system, and plasma MMA using a GC-MS
assay (23). To minimize interbatch variation, we assayed samples from
the same participant in the same batch; the mean intrabatch CV was
<3% for homocysteine and <8% for MMA.
Power calculations
Fedosov (24) suggested that patients with vitamin B-12 as high as
280 ng/L may be vitamin B-12 deficient. We assayed MMA in all
(n = 177) patients with baseline vitamin B-12 between 150 and 280 ng/L
and estimated this would yield 80% power to detect an increase of 42%
in mean MMA concentration after augmentation of FA, assuming there
was an effect, using a type 1 error at 0.05.
Ethics
In 2006, the Multicenter Research Ethics Committee (MREC) for Wales
gave ethical approval for FolATED, and the Medicines and Healthcare
products Regulatory Agency issued the Clinical Trial Authorization.
In 2009 the MREC gave additional permission to investigate the
interaction between FA and MMA.
Outcomes
The primary outcome was MMA concentration at week 12. The
secondary outcomes were serum folate, RBC folate, and serum vitamin
B-12; and homocysteine collected at week 12.
Outcome assessment timing and blinding status of
participants
Blood samples were drawn from the included participants to assess
the biochemistry outcomes at baseline and week 12. The participants,
and researchers taking the sample, were blinded to the allocation. The
analysts undertaking the initial analysis were pseudo-blinded during the
FolATED analysis (22). All researchers were unblinded at the timing of
the analysis for this study.
Statistics
Data analysis.
We followed the CONSORT reporting checklist for reporting a clinical
trial.
Baseline characteristics (age, gender, antidepressant, counselling,
marital status, number of children, employment status, smokers,
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FIGURE 1 CONSORT diagram of participants included from the FolATED trial. FolATED, Folate Augmentation of Treatment—Evaluation for
Depression; MMA, methylmalonic acid.
alcohol consumption, low or marginal serum vitamin B-12, plasma
MMA, serum folate, RBC folate, homocysteine) were summarized by
randomized group. For continuous variables, we reported both the
mean ± SD and median [IQR] values.
The primary and secondary outcomes were analyzed using a mixed-
effects linear regression, adjusting for fixed effects of randomized group
(FA or placebo) and baseline concentration, and with center as a random
intercept to account for heterogeneity across sites. The adjusted mean
differences (aMDs) are presented along with 95% CIs and P values.
A complete-case population was used throughout and reasons for
missingness were explored and used to determine any breaches of a
missing-at-random assumption.
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TABLE 1 Baseline characteristics for participants with “low” (150–219.9 ng/L) or “marginal”
(220–280 ng/L) serum vitamin B-121
Baseline characteristics Placebo (n = 85) Folic acid (n = 92) Total (n = 177)
Age, y
46.0 ± 11.6 46.3 ± 12.1 46.2 ± 11.8
46.9 [38.6–54.0] 47.1 [38.5–54.0] 46.9 [38.6–54.0]
Gender
Male 32 (37.6) 33 (35.9) 65 (36.7)
Female 53 (62.4) 59 (64.1) 112 (63.3)
Antidepressant
SSRI 56 (65.9) 62 (67.4) 118 (66.7)
Other 29 (34.1) 30 (32.6) 59 (33.3)
Counselling
Counselling 39 (45.9) 35 (38.0) 74 (41.8)
No counselling 46 (54.1) 57 (62.0) 103 (58.2)
Marital status
Single 15 (17.6) 19 (20.7) 34 (19.2)
Had a partner 21 (24.7) 11 (12.0) 32 (18.1)
Have a partner 49 (57.6) 62 (67.4) 111 (62.7)
Dependent children, n
0 52 (61.2) 58 (63.0) 110 (62.1)
1 13 (15.3) 11 (12.0) 24 (13.6)
2 12 (14.1) 13 (14.1) 25 (14.1)
≥3 8 (9.41) 10 (10.9) 18 (10.2)
Employment
Full-time employed 29 (34.1) 17 (18.5) 46 (26.0)
Part-time employed 20 (23.5) 31 (33.7) 51 (28.8)
Unemployed 36 (42.4) 44 (47.8) 80 (45.2)
Smoking status
Nonsmoker 54 (63.5) 59 (64.1) 113 (63.8)
Low (1–10/d) 16 (18.8) 11 (12.0) 27 (15.3)
Moderate (11–20/d) 11 (12.9) 17 (18.5) 28 (15.8)
High (≥21/d) 4 (4.71) 5 (5.44) 9 (5.09)
Alcohol consumption per week2
None 33 (38.8) 37 (40.2) 70 (39.5)
Within safe limit 41 (48.2) 43 (46.7) 84 (47.5)
Above safe limit 11 (12.9) 12 (13.0) 23 (13.0)
Serum vitamin B-12, ng/L
Low (150–219.9) 36 (42.4) 45 (48.9) 81 (45.8)
Marginal (220–279) 49 (57.6) 47 (51.1) 96 (54.2)
1Values are n, mean ± SD, or median [IQR]. SSRI, selective serotonin reuptake inhibitor.
2Safe limits: females = 14 units/wk; males = 21 units/wk.
aMDs were converted to standardized effect sizes and presented
alongside their associated 95% CI for each of the 5 outcomes. Stata
version 15 (StataCorp.2017. College Station, TX: StataCorp LLC) was
used throughout.
Sensitivity analysis.
A sensitivity analysis was carried out to assess the impact of including
patients with marginal vitamin B-12 at baseline. The analysis was
repeated only including patients with low vitamin B-12 at baseline.
Results
Of the 177 participants (Figure 1), Table 1 shows 81 had “low”
baseline serum vitamin B-12 between 150 and 220 ng/L (36 in
the placebo group, 45 in the intervention group) and another
96 had “marginal” baseline concentrations between 220 and
280 ng/L (49 in the placebo group, 47 in the intervention group).
The mean age was 46 y in the placebo group and 46.3 y in the FA
group. There were 32 males (37.6%) in the placebo group and
33 males (35.9%) in the FA group; all baseline characteristics
were similar across the 2 allocation groups.
Among participants with a low or marginal baseline serum
vitamin B-12 in the FolATED trial, 5 mg FA/d increased mean
serum and RBC folate in those allocated to receive it, from
5.8 μg/L and 383 μg/L at baseline to 27.9 μg/L and 830 μg/L
at week 12, respectively (Table 2).
Primary outcome analysis
There was no difference in the between-group plasma MMA
concentration; the aMD was −0.01 (95% CI: −0.06, 0.04;
P = 0.71).
Secondary outcome analyses
There was a strong statistically significant difference reported
at week 12 in serum folate (aMD: 21.6 μg/L; 95% CI: 18.1,
25.0 μg/L; P < 0.001) and RBC folate (aMD: 461 μg/L; 95%
CI: 388, 535 μg/L; P < 0.001), with greater concentrations
in the supplemented group than in the control group. There
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TABLE 2 Baseline and week 12 outcome measurements by treatment group1
Baseline Week 12
Placebo (n = 85) FA (n = 92) Placebo (n = 79) FA (n = 87)
Vitamin B-12, ng/L
226 ± 35.0 218 ± 36.2 234 ± 66.6 236 ± 61.2
230 [199–258] 221 [189–248] 222 [189–262] 227 [196–266]
Serum folate, μg/L
6.54 ± 3.81 5.80 ± 3.11 7.53 ± 6.91 27.9 ± 15.3
5.70 [3.70–9.00] 5.10 [3.55–6.85] 5.80 [3.50–9.00] 25.1 [18.0–36.9]
Plasma MMA, μmol/L 65 70 65 70
0.313 ± 0.165 0.302 ± 0.160 0.313 ± 0.159 0.300 ± 0.156
0.270 [0.190–0.340] 0.250 [0.180–0.360] 0.260 [0.200–0.390] 0.255 [0.190–0.350]
RBC folate, μg/L 75 81 61 56
380 ± 160 383 ± 171 366 ± 153 830 ± 262
343 [261–478] 337 [253–445] 327 [255–471] 925 [612–1040]
Homocysteine, μmol/L 83 89 76 79
12.8 ± 4.11 14.6 ± 10.4 12.6 ± 3.89 11.2 ± 9.25
11.9 [10.2–14.7] 12.8 [10.9–14.8] 11.9 [9.80–14.8] 10.0 [8.90–11.4]
1Values are n, mean ± SD, or median [IQR]. FA, folic acid; MMA, methylmalonic acid.
was no difference found in homocysteine (aMD: −1.83 μmol/L;
95% CI: −4.01, 0.35 μmol/L; P = 0.10) or serum vitamin B-
12 (aMD: 9.63 μg/L; 95% CI: −6.71, 26.0 μg/L; P = 0.25)
Table 3. However, caution is needed when interpreting the
effects on serum homocysteine and serum vitamin B-12 because
these analyses may be underpowered. All biochemical findings
are shown as standardized effect sizes to facilitate comparison
(Figure 2).
The missing data within the biochemistry outcomes were
explored and found to be due to the facilities’ inability to collect
and record all data. For example, 1 center was not able to collect
or process MMA or RBC folate data, thus we judged these as
missing completely at random (Table 4).
To determine whether an effect was concentrated within a
more inadequate vitamin B-12 status range, a subset analysis
of the 81 participants with vitamin B-12 <220 ng/L was
performed as a secondary sensitivity analysis. Within the sample
with a “low” vitamin B-12 baseline measure the between-group
MMA aMD was 0.01 (95% CI: −0.07, 0.09; P = 0.75), i.e.,
comparing the supplemented group with the control group.
Similar findings were reported for each of the biochemistry
measures, thus a low vitamin B-12 patient population exhibited
similar findings to those from a low or marginal population.
Discussion
The FolATED trial showed conclusively that FA does not
potentiate antidepressant medication (22). In this subgroup
of depressed but otherwise healthy participants with baseline
serum vitamin B-12 concentrations that were “low” (between
150 and 220 ng/L) or “marginal” (between 220 and 280 ng/L),
5 mg FA/d for 12 wk did not significantly change MMA
concentration.
Our study has several strengths. We believe this is the


























Standardized effect sizes 95% CI
FIGURE 2 Results from the mixed-effects linear regression presenting the adjusted mean differences (with associated 95% CIs) for the
biochemical outcomes. MMA, methylmalonic acid.
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TABLE 3 Mixed-effects regression of the biochemical outcomes, presenting the crude MD and aMD for folic acid supplementation –
placebo1
MD (95% CI) P value aMD (95% CI) P value
Plasma MMA concentration, μmol/L − 0.0131 (−0.0663, 0.0401) 0.63 − 0.00909 (−0.0673, 0.0392) 0.71
Vitamin B-12, ng/L 1.91 (−17.5, 21.4) 0.85 9.63 (−6.71, 26.0) 0.25
Serum folate, μg/L 20.2 (16.6, 23.8) <0.01 21.6 (18.1, 25.0) <0.01
RBC folate, μg/L 464 (387, 541) <0.01 461 (387, 535) <0.01
Homocysteine, μmol/L − 1.39 (−3.64, 0.856) 0.23 − 1.83 (−4.01, 0.352) 0.10
1aMD, adjusted mean difference; MD, mean difference; MMA, methylmalonic acid.
with low or marginal serum vitamin B-12, and the first to
examine the hypothesis that FA affects MMA concentration
in such individuals; this has not previously been challenged or
adequately replicated in the literature.
The fact that patients received FA alone in the FoLATED
trial makes it unique; in most other trials investigating FA,
participants are treated with a combination of FA plus vitamin
B-12 in order to avoid alleged adverse effects from FA.
It is also important to note that our study participants
had an average age highly similar to that of the NHANES
study (13). The concentrations of serum folate achieved in
our study were at least as high as those seen in previous
studies and homocysteine was lower after 12 wk in the group
receiving FA therapy; daily supplementation with 5 mg FA
is expected to reduce homocysteine blood concentration by
approximately one-quarter, according to our study’s baseline
values (i.e., from 14.6 μmol/L to 11 μmol/L) (25). Consistent
with this, homocysteine concentrations fell from baseline in the
FA-supplemented group to a mean of 11.2 μmol/L, although
there was no statistical difference in the week 12 between-group
mean difference (P = 0.10). Nevertheless, this fall, together
with the very high serum folate and RBC folate concentrations
achieved, does mean that biologically relevant metabolites are
altered by FA treatment, making the fact that there is absolutely
no change in MMA very interesting.
However, there are several important weaknesses. First, we
powered the FolATED trial to test whether FA potentiates
antidepressant medication. Because that limits power to
investigate MMA in low serum vitamin B-12 we set the
criterion for that at 220 ng/L rather than 200 ng/L (13); we
also extended MMA assays to those with “marginal” vitamin
B-12, because Fedosov (24) suggested they might also have
TABLE 4 Missing observations for each outcome by
randomized group1
Measure Placebo (n = 85) Folic acid (n = 92)
At baseline
Vitamin B-12 0 (0.0) 0 (0.0)
Plasma MMA concentration 20 (23.5) 22 (23.9)
Serum folate 0 (0.0) 0 (0.0)
RBC folate 10 (11.8) 11 (12.0)
Homocysteine 2 (2.35) 3 (3.26)
At 12 wk
Vitamin B-12 6 (7.06) 5 (5.44)
Plasma MMA concentration 20 (23.5) 22 (23.9)
Serum folate 6 (7.06) 5 (5.44)
RBC folate 24 (28.2) 36 (39.1)
Homocysteine 9 (10.6) 13 (14.1)
1Values are n (%). MMA, methylmalonic acid.
a vitamin B-12 insufficiency. Secondly, the exclusion criteria
for FolATED included a serum vitamin B-12 concentration
<150 ng/L. Hence, we cannot exclude the possibility that FA
increases MMA at very low serum vitamin B-12 concentrations.
However, ethical constraints on administering FA to vitamin B-
12–deficient patients will prevent any such trial being performed
(6, 20). We also cannot completely exclude the possibility of
a potential drug (antidepressant) and nutrient (FA) interaction,
although this would seem unlikely. Finally, the FolATED trial
population had a mean age of 46 y. Hence, we cannot exclude
the possibility that FA increases MMA in older people. It is also
possible that a longer exposure to FA might adversely influence
MMA concentrations.
Nevertheless, we found no evidence of an effect of high
daily doses of FA over 3 months on MMA concentrations.
Others have suggested that the association observed in cross-
sectional studies might be due to a direct adverse effect of
UMFA on vitamin B-12 metabolism (13). Unfortunately, we
did not directly measure UMFA in our study. Our findings
perhaps lend support to the alternative interpretation: that
an elevated folate concentration is a consequence of pre-
existing vitamin B-12 deficiency. This could arise either from
impaired cellular uptake of folate or from its increased efflux in
vitamin B-12 deficiency. There are no known mechanisms for
the former. The latter suggestion relates to the “methyl-folate
trap”whereby reduced conversion of 5-methyl-tetrahydrofolate
(5mTHF) to tetrahydrofolate, owing to reduced activity of the
vitamin B-12–dependent enzyme methionine synthase, leads to
egress of unconjugated 5mTHF into the circulation because
5mTHF is not a preferred substrate for folyl polyglutamate
synthase (15, 26). Although this might indeed explain the
observed cross-sectional association between MMA and serum
folate it is inconsistent with the increase in RBC folate
seen in our FA-supplemented patients (Tables 2, 3) and with
the observation by Miller et al. (19) of high RBC folate
associated with raised MMA in elderly vitamin B-12–deficient
individuals.
In 1 retrospective review the association between MMA and
folate occurred only in participants >60 y old with “low to
normal” serum vitamin B-12 (27). No association was apparent
in a group of university students with low serum vitamin B-
12 (28). The mean age of our participants was 46 y, hence we
cannot exclude the possibility that FA affects MMA in older
populations. Perhaps the association becomes more apparent
in the elderly, as age-related renal impairment slows MMA
excretion (29, 30).
These findings address an important public health issue (20)
of the impact of FA augmentation. FA increases RBC folate
and serum folate, but supplementation does not change plasma
MMA concentration in middle-aged individuals with serum
vitamin B-12 between 150 and 280 ng/L. With these constraints
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in mind, we suggest that FA does not affect biological pathways
leading to adverse health effects, nor vitamin B-12’s function
and its role in sustaining health (6), at least in young and middle-
aged subjects.
In conclusion, augmentation of FA did lead to a change in
RBC folate and serum folate but did not lead to any change
in MMA in patients with low or marginal serum vitamin B-
12. Further interventions, with a greater sample size and longer
duration of treatment, are ultimately required to determine
whether any biological interaction exists between FA intake and
serum MMA concentration.
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